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Background: Parkinson’s disease (PD) is a chronic neurodegenerative disorder. There is limited 
knowledge about the function of the hypothalamic-pituitary-adrenal axis in PD. The primary 
aim of this prospective study was to analyze diurnal salivary cortisol concentrations in patients 
with PD and correlate these with age, gender, body mass index (BMI), duration of PD, and pain. 
The secondary aim was to compare the results with a healthy reference group.
Methods: Fifty-nine PD patients, 35 women and 24 men, aged 50–79 years, were recruited. 
The reference group comprised healthy individuals matched for age, gender, BMI, and time 
point for sampling. Salivary cortisol was collected at 8 am, 1 pm, and 8 pm, and 8 am the next 
day using cotton-based Salivette® tubes and analyzed using Spectria® Cortisol I125. A visual 
analog scale was used for estimation of pain.
Results: The median cortisol concentration was 16.0 (5.8–30.2) nmol/L at 8 am, 5.8 (3.0–16.4) 
at 1 pm, 2.8 (1.6–8.0) at 8 pm, and 14.0 (7.5–28.7) at 8 am the next day. Total secretion and 
rate of cortisol secretion during the day (8 am–8 pm) and the concentration of cortisol on the 
next morning were lower (12.5 nmol/L) in the reference group. No significant correlations with 
age, gender, BMI, duration of PD, Hoehn and Yahr score, Unified Parkinson’s Disease Rating 
Scale III score, gait, pain, or cortisol concentrations were found.
Conclusion: The neurodegenerative changes in PD does not seem to interfere with the 
  hypothalamic-pituitary-adrenal axis. Salivary cortisol concentrations in PD patients were 
increased in the morning compared with the reference group, and were not influenced by motor 
dysfunction, duration of disease, or coexistence of chronic or acute pain.
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Introduction
Parkinson’s disease (PD) is a chronic progressive neurodegenerative disorder accompa-
nied by autonomic dysfunction and alterations in a number of regulatory mechanisms, 
including loss of circadian rhythms in dopaminergic systems and fluctuations in the 
kinetics of drugs used in treatment of the disease.1
Pain in PD is common. Our own investigations2 reveal an incidence of pain of 
about 60%. Other studies in this area reveal incidence rates of 40%–80%.3–7 The 
pathogenesis of pain in PD is probably complex. Degeneration of descending dop-
aminergic pain-inhibiting fibers from the midbrain is probably one of the central 
pathways. Dystonia, a motor symptom of PD, is a common explanation for pain. 
Direct effects of levodopa on pain sensation support the hypothesis of an influence 
of the regulating mechanisms of autonomic and inhibitory modulation of pain input 
in dopamine-dependent centers.8International Journal of General Medicine 2011:4 submit your manuscript | www.dovepress.com
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Typically, signs of PD are hypokinesia, rigidity, and 
tremor, also referred to as the motor symptoms of the 
  disease. Nonmotor signs, such as mood changes and pain, 
are frequent.9 The pathogenesis of the nonmotor symptoms 
is not fully understood, and concomitant endocrine dysfunc-
tions have been suggested. There have been few studies in 
PD on endocrinopathy, such as hypothyreosis and cortisol 
deficiency. Munhoz et al showed that the secretion of thyroid 
and cortisol hormones is changed in PD, possibly caused by 
disturbances in the hypothalamic-pituitary-adrenal axis.10 
A recent study by Aziz et al analyzed thyroid-stimulating 
hormone, free thyroxine, prolactin, and growth hormone, 
but not cortisol, in PD patients.11
Influences of aging and stress on the glucocorticoid   system 
may result in reduction of hormone production   capacity, 
impaired neuronal adaptive responses to environmental chal-
lenges, and increased vulnerability to stress-induced loss of 
hippocampal neurons.12 Aging is hypothesized to alter the 
function of the hypothalamic-pituitary-adrenal axis in both 
men and women. Increasing cortisol concentrations, especially 
nocturnal concentrations,13,14 have been described. Some stud-
ies have indicated that there are gender differences.13–16 One 
study showed significantly higher evening cortisol concentra-
tions with increasing age, regardless of gender, while in the 
mornings this pattern was seen only in men. Diurnal cortisol 
variations were lower in older women but not in men.17
Studies of plasma cortisol in PD have shown variable 
results. Higher cortisol concentrations have been reported 
in untreated PD patients without dementia compared with 
healthy controls,18,19 and also compared with age-matched and 
gender-matched patients with Alzheimer’s disease. However, 
another study found decreased plasma cortisol concentrations 
in untreated PD patients compared with healthy controls, 
  suggesting that this may be a consequence of hypothalamic/
hypophyseal disturbance. Further, a previous study showed 
higher plasma cortisol concentrations in the evening and 
during the night in PD patients.18 One study reported higher 
concentrations of adrenocorticotrophic hormone in a sub-
group of PD patients (both demented and nondemented) 
found to be dexamethasone nonsuppressors, suggesting 
higher concentrations of corticotrophin-releasing hormone.20 
This surprisingly high incidence of dexamethasone non-
suppression in patients with PD could indicate a possible 
central pathologic disturbance of neurotransmitter function. 
However, levodopa medication and dopamine alone exert 
no influence on corticotrophin-releasing hormone, and the 
effects of other PD medications (such as dopamine agonists) 
on cortisol concentrations have not been studied.
In one study, acute levodopa intake has been shown to 
induce lower plasma cortisol levels in patients on long-term 
treatment for PD who were depleted of antiparkinsonian 
medication for 12 hours.21 We believe that description of 
the diurnal salivary cortisol concentration curve in patients 
with chronic neurodegenerative diseases, such as PD, could 
be of great interest for future studies of pharmacological and 
nonpharmacological interventions, with the aim of reducing 
stress-related symptoms and lifelong suffering.
The primary aim of this study was to measure salivary 
cortisol concentrations in a well-defined group of PD patients, 
with and without chronic PD-related pain, with regard to age, 
duration of disease, body mass index (BMI), motor function 
(Unified Parkinson’s Disease Rating Scale [UPDRS] III, gait) 
and influence of concomitant pain. The secondary aim was 
to compare the salivary cortisol concentrations in these PD 
patients with those in a healthy reference group, matched by 
age, gender, and BMI.
Methods and materials
Patients
Patients with stable and well-defined PD22 for more than 
two years, who were aged 40–80 years, with chronic pain 
(PD-P) or without chronic pain (PD no-P), were recruited 
from the outpatient departments of three medium-sized city 
hospitals in southern Sweden. The study was approved by 
the ethics committees at the University of Gothenburg and 
the University of Linkoping.
A period of two years since receiving the diagnosis of PD 
was chosen to decrease the risk of recruiting patients with an 
incorrect diagnosis, given that a number of other disorders 
can mimic PD. The individual course of PD is variable, and 
in our study the range of disease duration was 2–27 years 
(median 5–6 years). Stable PD was defined as lack of severe 
fluctuations of the disease (on-off symptomatology) in terms 
of need for frequent extra doses of antiparkinsonian medica-
tion and absence of dementia. Exclusion criteria were severe 
fluctuations in PD, concurrent epilepsy, active malignancy, 
polyneuropathy, or other serious disease of somatic or 
  psychiatric origin that could interfere with the study. Patients 
with severe abnormalities of blood parameters, electrolytes, 
liver or renal parameters, including bilirubin .20 mmol/L, 
serum creatinine .130 mmol/L, SR .30 mm, fasting 
plasma glucose .6.7 mmol/L, were excluded. Patients 
on corticosteroids (oral, nasal, or inhalation), insulin, 
antiepileptic drugs, or medication for dementia, and those 
  participating in other therapeutic or pharmacological studies 
were also excluded.International Journal of General Medicine 2011:4 submit your manuscript | www.dovepress.com
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Chronic pain was defined as the occurrence of PD-
related pain on at least three days per week during the 
three months prior to recruitment. A reference population 
consisting of healthy individuals, matched by gender, age, 
and BMI, were recruited from another project,17 and con-
sisted of 1700 healthy men and women aged 30–80 (mean 
48) years. These individuals were recruited from the same 
catchment area as our patients, and their cortisol levels were 
analyzed using the same method and in the same laboratory. 
Demographic and clinical characteristics of the population 
with PD and the reference group are presented in Table 1.
Methods
Motor function was assessed by the UPDRS.23 Duration 
and severity of pain was measured using a visual analog 
scale (VAS)24 for five consecutive days before sampling. 
Maximal pain during each of these five days was registered 
in our protocol.
Collection of salivary cortisol samples for both groups 
was done in the community using a technique which has 
been well described elsewhere.25–29 To summarize, patients 
were instructed to have no intake of food within 30 minutes 
of sampling. Samples were taken at four time points, ie, at 
8 am, 1 pm, and 8 pm, and then at 8 am the next morning. 
Cotton-based neutral Salivette® tubes (Landskrona, Sweden) 
were used. A swab was chewed for two minutes and then 
placed in a sterile plastic tube. This was then put in the 
patient’s refrigerator at home. The tubes for each patient 
were collected and sent by post to the laboratory within three 
days. The Salivette tubes were then centrifuged at 1711 G 
for 15 minutes at 20°C, and then frozen at −80°C until 
assayed. A commercial radioimmunoassay-based technique 
for   measurement of salivary cortisol was used (Spectria™ 
Cortisol I125, Landskrona, Sweden). Total cortisol secretion 
during the day (8 am–8 pm) and during the night (8 pm–8 am) 
was calculated using the formula for area under the curve 
from the zero level (AUC0–AUCG), and the increase in cor-
tisol secretion from the baseline level during the same time 
interval (AUCi) was calculated according to the method 
reported by Pruessner et al30 and Fekedulegn et al.31 The latter 
author has shown significant associations (r . 0.7; P = 0.001) 
between AUCG and cortisol concentrations. All analyses of 
saliva from the same person were performed at the same time 
to minimize interassay variance.
Statistical analysis
STATISTICA version 8.0 (Statsoft Inc, Tulsa, OK) and SPSS 
version 18.0 (SPSS Inc, Chicago, IL) were used for the sta-
tistical evaluations. Nonparametric, Mann–Whitney U, and 
Wilcoxon paired signed-rank tests were used. The Spearman’s 
rank correlation test was also used. The Wilcoxon signed-
rank test for one sample was used when comparing median 
salivary cortisol levels in PD patients with the median in the 
reference population.
Results
Fifty-nine patients, consisting 24 men and 35 women aged 
50–79 years of age (median 66.5/67.5 years for men/women) 
were recruited for this study. The PD-P group comprised 
43 patients (16 men and 27 women aged 50–77 years [median 
63/66 years for men/women]), and the PD no-P group com-
prised eight men and eight women (median 70/75 years for 
men/women). Age at onset of PD was 40–74 years (median 
60.0) and duration of PD was 2–27 years, with a median of 
5.0/6.0 years for men/women, respectively. Most patients 
(96%) were over 55 years of age at the start of the study. 
No patient was younger than 64 years in the PD no-P group 
compared with 18 of 43 (42%) patients in the PD-P group.
Time of awakening in the PD-P and PD no-P groups 
did not differ significantly, and varied from 4.35 am to 
8.00 am on the two days when sampling took place. Time 
points for sampling varied in relation to specified time 
points, ie, 8 am (±30 minutes), 1 pm (−60/+30 minutes) and 
8 pm (−95/+75 minutes). Time intervals between awaken-
ing and sampling in the morning were 0–220 minutes and 
5–187 minutes in the PD-P group and PD no-P group, 
respectively, and in 10 patients was less than 45 minutes. 
A cortisol arousal reaction with an increase in salivary cor-
tisol of 2.5 nmol/L was noted in only one patient.
Maximal pain in the PD patients during the five days 
prior to inclusion were calculated on the VAS scale as the 
median (10/90 percentiles), with a value of 6.2 (2.8/9.1) and 
Table 1 characteristics of the PD population and the healthy reference group
Group Sex Number Ageb Weighta BMIa UPDRS IIIa,b
PD Male 24 50–78 84.1 26.8 20.1 (8–37)
Female 35 60–79 68.4 25.5 22.0 (3–57)
referencea Male 303 50–74 – 26.9 –
Female 305 50–74 – 26.8 –
Note: Values are given as meana and rangeb.
Abbreviations: PD, Parkinson’s disease; UPDRS, Unified Parkinson’s Disease Rating Scale.International Journal of General Medicine 2011:4 submit your manuscript | www.dovepress.com
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minimal pain of 3.0 (0.0/6.5). Motor function as estimated 
by UPDRS III scores was 3–57, corresponding to mild to 
severe PD (see Table 1).
Basal salivary cortisol
Salivary cortisol concentrations varied over a 24-hour period, 
as shown in Figures 1A and 1B. Individual salivary corti-
sol values in the PD-P and PD no-P patients are shown in 
Figure   1A. There were no statistically significant differences 
in salivary cortisol concentrations between the two groups. 
One patient in the PD no-P group had extremely high values 
(174.6, 22.3, 14.6, and 110 nmol/L).
Salivary cortisol concentrations at 8 am, 1 pm, 8 pm, and 
8 am, along with delta values, are shown in Tables 2A and 
2B. Morning cortisol concentrations were higher in the PD 
group compared with the reference group, and the concentra-
tion was not dependent on time interval between awakening 
and time point of salivary sampling. There was also no dif-
ference in cortisol concentration between   participants taking 
their levodopa medication within one hour either side of 
salivary sampling. The linear equation for the cortisol trend 
curve calculated to estimate AUC was y = 23.56–1.02x 
versus y = 17.84–0.69x for the PD and reference groups, 
respectively.
Total cortisol secretion and secretion 
rate
Total cortisol secretion during the day (8 am–8 pm, 
AUC0–AUCG) was significantly increased in PD patients, 
at 112.8 nmolh versus 81.1 nmolh in the reference group 
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(P , 0.001). The corresponding value for 8 pm–8 am in PD 
patients was 109.8 nmolh. The decrease in the salivary   cortisol 
secretion rate during the day (8 am–8 pm, negative AUCi) 
in the PD and reference groups was −73.7 nmolh   versus 
−49.9 nmolh. This difference was statistically   significant 
(P = 0.001). The increase in salivary cortisol secretion rate 
during the night (8 pm–8 am, AUCi) was 72.6 nmolh, and 
similar to the day time value.
Somatic status and symptom correlations 
with cortisol
There was a highly significant correlation (r = 0.44; P , 0.01) 
between values at 8 am on day 1 and 8 am on day 2. There were also 
significant correlations between cortisol concentrations at 1 pm 
and for all other time points (r values 0.28–0.42; P 0.001–0.034). 
No significant correlations between BMI, motor dysfunction, 
measured as UPDRS III # 20 compared with .20, gait (UPDRS 
III, item 30), acute pain (maximum VAS at screening), chronic 
pain, and cortisol concentrations were identified.
Discussion
In this study, we compared salivary cortisol concentrations 
in a group of patients with a diagnosis of PD for more 
than two years with those in a reference group of gender-, 
BMI-, and age-matched healthy individuals.17 There were 
two groups of PD patients, ie, those with and those without 
PD-related pain.
The cortisol concentrations in this study were unrelated 
to age. This is in disagreement with the hypothesis that aging 
alters the function of the hypothalamic-pituitary-adrenal axis 
in both men and women. Increasing cortisol concentrations, 
especially at night, have been described previously.13,16 Even 
in our reference group, significantly higher evening cortisol 
concentrations were found with increasing age, regardless 
of gender, while in the mornings this pattern was seen only 
in men.17
We found no gender differences in cortisol rhythm and/or 
amplitude in our PD patients. This is in contrast with findings 
in our reference group, where differences were found for cor-
tisol concentrations in the morning, and the diurnal variations 
in cortisol were lower in older women but not in men. Other 
studies have also indicated gender differences.13–16
For estimation of total secretion and the secretion rate 
of cortisol, we analyzed AUC0–AUCG for cortisol during 
the daytime (8 am–8 pm) according to the recommenda-
tions of Fekedulegn et al.31 The results were significantly 
higher in the PD group than in the reference group. The 
corresponding value for nocturnal AUCG (8 pm–8 am) was 
similar. The decreasing secretion rate (negative AUCi) was 
significantly higher in the PD group. Our results showing 
a significant increase in secretion rate and total cortisol 
  secretion are potential evidence for a well functioning   adrenal 
and hypothalamic-pituitary-adrenal axis, as reported by 
Fekedulegn et al.31
The excellent correlation between salivary cortisol levels 
and plasma total and free biologically active cortisol levels 
in healthy men and women was reported as early as 1983 
by Vining et al,32 and this was confirmed in a subsequent 
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Figure 1B Diurnal salivary cortisol concentrations (nmol/L) in all 59 patients with Parkinson’s disease. Statistical analysis, between paired time points.
Notes: correlations – Spearman two-tailed test: 8 am–8 am, r = 0.44: P , 0.01; 1 pm–8 am, r = 0.39: P , 0.01. 
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study.33 This method has been the “gold standard” for esti-
mating stress in psycho-biologic-endocrine research for a 
number of years.34 A recent report by Törnhage described 
the usefulness of salivary cortisol for assessing the 
  hypothalamic-pituitary-adrenal axis.27 These observations 
make it appropriate and convenient to use salivary cortisol 
sampling at home as a pain-free, simple, repeatable, and 
useful method for assessment of the hypothalamic-pituitary-
adrenal axis.
Cortisol as a reflector of chronic stress in chronic disease 
has not undergone adequate investigation, although some 
studies have been performed. PD has several potentially 
stressful nonmotor symptoms, such as pain, mood change, 
and autonomic dysfunction, all of which could result in 
changes in cortisol secretion.
The time point for sampling in the evening differed 
between the PD and reference groups. Sampling occurred 
about two hours later in the reference group. We believe 
that the consequences of this are trivial, because we know 
that the negative slope is minimal between 8 pm and 10 
pm.35 We also estimated the linear equation for salivary 
cortisol in both groups. When we adjusted for the time dif-
ference, the salivary cortisol concentration at 8 pm in the 
reference group was 4.0 nmol/L compared with 3.2 nmol/L 
in the PD group, and this difference was not statistically 
significant.
The fact that the time point for awakening corresponds to 
sleep duration is important. A previous study found a positive 
correlation between sleep duration and cortisol concentration.35 
The time interval from awakening in the morning to the 
exact time point of sampling is also   important because of 
the cortisol arousal reaction. In our study, we registered the 
exact time for sampling in all patients in order to control for 
both the cortisol arousal reaction and food intake. For most 
patients in our study, the exact time points for sampling were 
in accordance with those stipulated and stated for the reference 
group (±30 minutes). In 11 patients, the time interval was less 
than 60 minutes. In seven of these 11 patients, the interval was 
30–45 minutes, with a high risk for an arousal effect. There was 
a cortisol arousal reaction in only one of 59 participants.
We found that patients in both PD groups generally 
showed a similar 24-hour rhythm of cortisol secretion. 
However, morning cortisol concentrations were higher in 
the PD group compared with those in the reference group. 
This is in disagreement with the findings of Hartmann et al, 
who reported normal morning plasma cortisol but increased 
concentrations in the evening and at night.18
Our hypothesis that chronic neurodegenerative disease, 
using PD as an example, could change hypothalamic-
pituitary-adrenal axis function was not confirmed. However, 
we found no correlation between duration of disease and 
cortisol concentrations. Some patients in our study showed 
very high morning salivary cortisol concentrations on both 
days. Function of the hypothalamic-pituitary-adrenal axis 
seems to be optimal, even at this age and after many years 
of disease. This, in turn, could indicate a normal-functioning   
Table 2A comparisons of salivary cortisol concentrations (nmol/L) in PD patients with (PD-P) and without chronic PD-related pain   
(PD no-P) and the reference group
Group Sex (n) Day 1 Day 2
8 am 1 pm 8 pm 8 am
Geom mean 
median  
with (10th and  
90th perc)
P-valueb Geom mean  
median with  
(10th and  
90th perc)
Geom mean  
median  
with (10th and  
90th perc)
P-valueb Geom mean 
median with  
(10th and 90th 
perc)
PD-P Male (16) 12.5 5.6 2.3 15.1
14.8 (5.2–20.3) 0.215 5.6 (3.2–11.8) 2.6 (1.1–5.1) 0.016d 14.2 (5.1–35)
Female (27) 15.6 6.4 3.4 15.1
17.9 (5.8–30) 0.021d 6.2 (2.6–21.2) 2.9 (1.6–8.5) 0.614 15.4 (7.6–28.6)
PD no-P Male (8) 20.5 6.4 4.2 16.9
15.4 (5.7–174.6) 0.128 6.5 (2.1–22.3) 3.1 (2.2–14.6) 0.779 12.9 (4.6–110)
Female (8) 17.5 5.3 2.8 13.0
16.8 (7.8–38.2) 0.091 5.6 (3.5–8.0) 2.6 (2–5.5) 0.035d 12.1 (7.6–23.2)
reference Male (303) 12.1a – – 3.9c – –
Female (305)12.5a – – 4.1c – –
Notes: aValues are given as geometric mean; btesting median of the corresponding reference population; cvalues were estimated according to equations of lines between   
8 am and 10 pm; dstatistically significant at 5% level.
Abbreviations: Geom, geometric; perc, percentiles; PD, Parkinson’s disease; PD no-P, PD without pain; PD-P, PD with pain.International Journal of General Medicine 2011:4 submit your manuscript | www.dovepress.com
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hypothalamic-pituitary-adrenal axis in individuals with PD, 
thereby not supporting the hypothesis of earlier studies by 
Rabey et al20 and Bellomo et al36   concerning   pathophysiological 
changes at the hypothalamic-  hypophyseal-adrenal level.
There were marked differences in motor function of the 
patients according to UPDRS III scores. We predicted that 
motor dysfunction would be a severe stress factor resulting in 
increased cortisol concentration, but this was not confirmed. 
We found no correlation between gait problems, defined by 
UPDRS III item 30, and salivary cortisol concentration. This 
is in disagreement with Charlett et al who found a positive 
correlation between gait problems and plasma cortisol con-
centrations.19 The reason for this difference is not obvious.
In this study, there was no correlation between BMI and 
cortisol concentrations in either the PD group or the reference 
group. In contrast, a study by Travison et al found a negative 
correlation between BMI and morning cortisol.37
The hypothalamic-pituitary-adrenal axis seems to be pre-
served in patients with PD. Effects of acute or chronic pain were 
not seen in our study, in contrast with the findings by Heim 
et al.38 The “glucocorticoid cascade hypothesis,” as described by 
McEwen,12 ie, an acquired or primary decrease in hippocampal 
glucocorticoid receptor numbers leads to a reduction in cen-
tral feedback sensitivity that results in basal glucocorticoid 
hypersecretion, is partially confirmed in our study. Possibly, the 
night-time lack of antiparkinsonian dopaminergic substitution 
contributes to the elevated cortisol concentration in the morn-
ing. The limitation of our study is the relatively small numbers 
of PD patients (n = 59), although this number compares well 
with those used in earlier studies in this field.19,20
Conclusion
PD patients with mild to severe PD have a normal diurnal 
cortisol rhythm, and higher morning cortisol concentrations 
and increased cortisol secretions during the day (8 am–8 pm) 
compared with healthy age-matched and gender-matched 
individuals. PD patients seem to have a normal cortisol 
arousal reaction and hypothalamic-pituitary-adrenal axis 
function, and their cortisol concentration is unrelated to age, 
duration of disease, gender, severity of motor dysfunction, 
and BMI, supporting the hypothesis that this neurodegen-
erative disorder itself does not interfere with hypothalamic-
pituitary-adrenal axis function.
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